Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B
Viruses · 08.11.2025 · 17 (11) · 1484
DOI: 10.3390/v17111484 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Viruses, online erschienen am 08.11.2025. Verfasst von Qiqi Ning und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. Hauptthemen laut MEDLINE: Infectious Disease Transmission, Vertical, Hepatitis B, Hepatitis B, Chronic, Hepatitis B e Antigens. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 113 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, NIH HHS, National Institutes of Health.
Abstract (Originalsprache)
Chronic hepatitis B virus (HBV) infection is a major health problem that leads to approximately one million deaths every year worldwide. Mother-to-child transmission (MTCT) is the major cause of chronic HBV infection. HBV e antigen (HBeAg) is a secretory viral protein and modulates the immunological landscape of the newborn to promote HBV persistence. HBeAg actively reprograms innate and adaptive immunity. Mechanistically, HBeAg regulates macrophage polarization, suppresses dendritic cell and natural killer (NK) cell activities, impairs T cell and B cell functions, and promotes the expansion of myeloid-derived suppressor cells (MDSCs). These multifaceted effects contribute to immune tolerance and persistent HBV infection in the offspring of carrier mothers. Clinically, HBeAg status is a critical determinant for MTCT risk stratification and intervention, particularly in resource-limited settings. Despite advances in neonatal immunoprophylaxis and maternal antiviral therapy, residual transmission of HBV persists. Emerging approaches targeting HBeAg directly or restoring antiviral immunity offer promising avenues for breaking immune tolerance and achieving HBV elimination. This review summarizes current understanding of HBeAg-mediated immune modulation and highlights strategies that are being used to disrupt MTCT and treat HBV patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Molecular Microbiology and Immunology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA.
ORCID-Profile: Jing-Hsiung James Ou
Förderung
- NIAID NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Ning, Q., & Ou, J. J. (2025). Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B. Viruses, 17(11), 1484. https://doi.org/10.3390/v17111484
Vancouver
Ning Q, Ou JJ. Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B. Viruses. 2025;17(11):1484. doi:10.3390/v17111484
BibTeX
@article{Ning2025,
author = {Ning, Qiqi and Ou, Jing-Hsiung James},
title = {Hepatitis B Virus e Antigen in Mother-to-Child Transmission and Clinical Management of Hepatitis B},
journal = {Viruses},
year = {2025},
volume = {17},
number = {11},
pages = {1484},
doi = {10.3390/v17111484}
}
EUVIMED